Completed
Topics
Temporomandibular disorders (TMDs) are disorders associated with the temporomandibular joint and the muscles and tissues of the jaw. At the request of the National Institute of Dental and Craniofacial Research and the Office of the Director (NIH), this consensus study will assess the current state of TMD research, education, care, and its public health significance. The committee will identify multidisciplinary approaches necessary to the development and implementation of safe and effective clinical treatments for TMD, as well as strategies to advance TMD research and education.
Featured publication
Consensus
·2020
Temporomandibular disorders (TMDs), are a set of more than 30 health disorders associated with both the temporomandibular joints and the muscles and tissues of the jaw. TMDs have a range of causes and often co-occur with a number of overlapping medical conditions, including headaches, fibromyalgia,...
View details
Description
An ad hoc committee under the auspices of the National Academies of Sciences, Engineering, and Medicine’s Health and Medicine Division will convene to address the current state of knowledge regarding TMD research, education and training, safety and efficacy of clinical treatments of TMD, and burden and costs associated with TMD. The ad hoc committee will identify approaches to advance basic, translational, and clinical research in the field. The committee’s findings, conclusions, and recommendations will also inform development of policies related to evidence-based treatment and clinical management of TMD patients.
Specifically, the committee will:
---Review and estimate the public health significance of TMDs, including prevalence, incidence, burden and costs; and review challenges to data collection and reliability.
---Evaluate the evidence base for assessment, diagnosis, treatment, and management of acute and chronic TMD. Recognizing that TMDs are diverse and multifactorial conditions influenced by genetics, sex and gender, environmental, physiological, and psychological factors, this effort will:
- Address patient heterogeneity and challenges to patient stratification to better target therapies toward patients.
- Identify similarities and differences between chronic TMD, other chronic pain states (as well as chronic overlapping pain conditions), and other joint disorders such as phenotypic features that might predict responsiveness to treatments.
- Identify and characterize other non-pain comorbidities that diminish quality of life, including those that affect etiology and influence resilience, such as nutritional challenges and other neurological, metabolic, and mental health conditions (e.g. anxiety, depression).
- Examine the evidence-base for defining chronic TMD as a multi-system disorder that necessitates multidisciplinary research and interventions.
---Identify barriers to appropriate patient-centered TMD care, in the presence and absence of an evidence base, and strategies to reduce these barriers along the continuum of TMD pain. This effort will:
- Evaluate elements and outcomes of patient-centered TMD care.
- Identify challenges to dissemination and implementation of evidence-based treatments and prevention strategies that are safe and effective.
- Determine and characterize health inequities in clinical TMD management.
---Review the state of science for TMD and provide an overview of basic, translational, and clinical research for TMD. This effort will:
- Examine existing or emerging TMD animal models and their preclinical utility.
- Identify gaps and opportunities in TMD research relating to central and peripheral mechanisms, genetic/epigenetic contributions, heterogeneity of molecular mechanisms, joint mechanics, neuroimmune processes, endocrine influences, role of the microbiome, and endogenous mechanisms of resilience.
- Assess the intersection of sex differences in immune/neuroimmune and inflammatory responses in chronic TMD with other autoimmune diseases that are more prevalent in females or males.
- Assess progress on identification and validation of targets and biomarkers (genetic, neuroinflammation, neuroimaging, proteomic, behavioral, etc.) for use in establishing risk, diagnoses, treatment, outcomes, and reoccurrence.
- Identify potential approaches to using artificial intelligence for pattern recognition in patient datasets (e.g., genetic, biological, psychological, social traits, electronic health records, and patient-reported outcomes) to distinguish disease subtypes, develop individualized clinical decision support, and predict patient responses.
- Identify new and rapidly evolving tools and technologies with potential to significantly advance research, diagnosis, and treatment of TMD.
---Identify opportunities and challenges for development, dissemination, and clinical implementation of safe and effective clinical treatments for TMD, including pharmacological agents, regenerative medicine, behavioral interventions, and complementary and integrative approaches.
---Identify scientific and clinical disciplines needed to advance TMD science and the development, dissemination, and implementation of safe and effective treatments, as well as strategies to enhance education and training in these disciplines.
---Identify multidisciplinary/interdisciplinary research approaches necessary in the short-and long-term to advance basic, translational, and clinical TMD research and to improve the assessment, diagnosis, treatment, and management of TMDs.
Collaborators
Committee
Chair
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Committee Membership Roster Comments
Roster was updated on 03/14/2019 to reflect the addition of 4 new committee members, Dr. Cory Resnick, Dr. Antony Rosen, Dr. Barbara Vickrey, and Dr. Hai Yao. Note: There was a change in the Committee Membership with the resignation of Dr. Allan Basbaum effective 01/24/19. Committee Roster was updated on 01/15/2019 to reflect the addition of 2 new committee members, Dr. David Deitz and Dr. Francis Keefe.
Committee Roster was posted originally on 01/09/2019.
Sponsors
National Institute of Dental and Craniofacial Research
Office of the Director (National Institutes of Health)
Staff
Cathy Liverman
Lead
Rebecca English
Lead
Olivia Yost
Kendall Logan
Major units and sub-units
Health and Medicine Division
Lead
Board on Health Care Services
Lead
Board on Health Sciences Policy
Lead